Buserelin

Suprefact Depot 3 Months

9.45 MG ImplantCanadaNot marketedAuthorised 24 Feb 2000

In other countries

The same active substances on other registers, the same brand first.

Suprefact DepotBrazil · Sanofi-Aventis Farmacêutica LtdaSame brand
SUPREFACT DEPOT 9,45 mg IMPLANTESpain · 9,9 mg · implante · Cheplapharm Arzneimittel GmbhSame brand
SUPREFACT DEPOT 6,3 mg IMPLANTE EN JERINGA PRECARGADASpain · 6,6 mg · implante · Cheplapharm Arzneimittel GmbhSame brand
SUPREFACT 1 mg/ml SOLUCION INYECTABLESpain · 1,050 mg · solución inyectable · Cheplapharm Arzneimittel GmbhSame brand
SuprefactItaly · Impianto · Cheplapharm Arzneimittel GMBHSame brand
Suprefact Depot 3 maanden, implantatiestift 9,45 mgNetherlands · Implantaat · CHEPLAPHARM Arzneimittel GmbHSame brand

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Suprefact Depot 3 maanden, implantatiestift 9,45 mgNetherlands · Implantaat · Medcor Pharmaceuticals B.V.

AnyNew Zealand · Inj 1 mg per ml, 5.5 ml vial

Documents

The official texts, at the regulator.

Register entryHealth Canada

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Health Canada, Canada

Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada · Added 13 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Buserelin
Strength: 9.45 MG
Dosage form: Implant
Route: Subcutaneous
Register: Canada (Health Canada)
Status: Not marketed
Status in the register: Dormant
Authorised: 24 Feb 2000
Registration: DIN 02240749
Marketing authorisation holder: Cheplapharm Arzneimittel GMBH
ATC code: L02AE01
Group: Antineoplastic and immunomodulating agents
Supply: PRESCRIPTION

Health Canada

SuprefactBuserelin · 100 MCG / ACT · SolutionCanadaCancelled

Suprefact Inj 1MG/MLBuserelin · 1 MG / ML · LiquidCanadaCancelled

Suprefact Intranasal Solution 1MG/MLBuserelin · 1 MG / ML · SprayCanadaCancelled

Suprefact Liq 1MG/MLBuserelin · 1 MG / ML · LiquidCanadaCancelled